Bromelain and NAC for Spike Protein: Dual Protease Strategy Explained

While nattokinase gets the headlines, two other compounds—bromelain and N-acetylcysteine (NAC)—attack the spike protein through entirely different biochemical mechanisms. Understanding how these work, individually and in combination, reveals why multi-agent approaches may be more effective than any single compound.

Bromelain: The Cysteine Protease from Pineapple

Bromelain is a cysteine protease enzyme extracted from pineapple stems. Its mechanism against spike protein is fundamentally different from nattokinase (a serine protease): bromelain targets both the virus's spike protein and the host cell's entry machinery simultaneously.

Triple-Target Mechanism (Sagar et al., 2021 — University of Nebraska Medical Center)

The landmark study published in Clinical and Translational Medicine (peer-reviewed, UNMC/FDA collaboration) demonstrated three simultaneous actions:

1. ACE2 receptor degradation: Bromelain reduced ACE2 expression in a dose- and time-dependent manner in VeroE6 cells (2-hour onset at 75 μg/mL in serum-free conditions)
2. TMPRSS2 degradation: Reduced expression of the host protease required for spike protein activation
3. Direct spike protein cleavage: Dose- and time-dependent degradation of the spike ectodomain, with complete cleavage at 25 μg/mg total protein within 10 minutes at 37°C

The study confirmed this is enzymatic activity (blocked by cysteine protease inhibitor E-64 and by heat inactivation). Most critically: bromelain pre-treatment significantly reduced live SARS-CoV-2 viral infection in both VeroE6 (p = 0.0021 for binding; p = 0.0010 for viral RNA) and Calu-3 cells (p = 0.0099).

BromAc: The Bromelain + NAC Combination (2025)

A pivotal 2025 study in Scientific Reports tested BromAc (bromelain combined with acetylcysteine) against the SARS-CoV-2 Omicron variant in both laboratory and human clinical samples:

• In vitro: BromAc at non-cytotoxic concentrations (250 μg/mL) was effective against infectious Omicron virus particles
• Ex vivo (human tracheal aspirates from ICU patients): BromAc cleaved the S1 spike subunit 100-fold more intensely than controls (p < 0.05) within 30–50 minutes
• Flow cytometry: BromAc at 250 μg/mL significantly reduced spike protein expression in epithelial cells from patient tracheal aspirate samples
• Mechanism: BromAc penetrates mucus and disrupts the spike protein through complementary actions—bromelain cleaves glycosidic linkages, while NAC reduces disulfide bonds

NAC: Disrupting Spike Protein's Structural Architecture

N-acetylcysteine (NAC) works through an entirely different mechanism: it attacks the disulfide bonds that hold the spike protein in its functional shape.

The Disulfide Bond Vulnerability

SARS-CoV-2 spike protein contains 30 cysteine amino acids forming 15 intra-molecular disulfide bonds. Four of these are in the receptor binding domain (RBD):

• Cys336–Cys361: Stabilizes β-sheet core structure
• Cys379–Cys432: Stabilizes β-sheet core (allosteric role confirmed)
• Cys391–Cys525: Stabilizes β-sheet core (most solvent-accessible, primary NAC target)
• Cys480–Cys488: Connects loops at the distal RBM (most stable, resistant to reduction)

How NAC Breaks These Bonds

Research from multiple groups (Pastore et al., J Biomol Struct Dyn, 2024; Moolla et al., PNAS, 2022) established NAC's mechanism:

1. Thiol/disulfide exchange: NAC's free thiol group (-SH) attacks the solvent-accessible Cys391–Cys525 disulfide bond
2. Covalent conjugation: NAC forms a new Cys525-S-S-NAC linkage (confirmed by mass spectrometry)
3. Conformational collapse: Breaking this bond causes the N- and C-termini of the spike NTD to separate from 9.9 Å to 130.2 Å—a dramatic unfolding
4. Binding affinity reduction: ACE2 binding affinity decreases threefold, with 5 Kcal/mol less free energy release

Antiviral confirmation: NAC caused 54.3% inhibition of SARS-CoV-2 replication in VeroE6 cells at 48 hours post-infection (vs. 99.8% for remdesivir).

NAC's Additional Relevance to Long COVID

Beyond direct spike protein disruption, NAC provides:

• Glutathione precursor: Restores cellular redox balance depleted by chronic inflammation
• von Willebrand factor disintegration: Acts as "medical revascularization" in COVID-associated intravascular thrombosis
• TNF-α and IL-6 suppression: Inhibits pro-inflammatory cytokine gene expression
• Mucolytic activity: Well-established clinical use for decades (commonly 600 mg twice daily)

Why the Combination Matters: Complementary Mechanisms

The McCullough protocol review (Cureus, 2023) specifically notes: "The combination of NAC with bromelain has been shown to synergistically disrupt spike protein by breaking glycosidic linkages and disulfide bonds."

Dosing and Safety

• Bromelain: 500 mg once daily on empty stomach. Safe at 200–2,000 mg/day. Main risk: amplified bleeding, pineapple allergy. Avoid with anticoagulants without physician guidance.
• NAC: 600 mg twice daily. Decades of clinical safety data. FDA briefly attempted to restrict supplement sales in 2020 (reversed). May interact with nitroglycerin.
• Combination: No known dangerous interactions between bromelain and NAC. Both can amplify bleeding risk with anticoagulant medications.

The Bottom Line

Bromelain and NAC attack spike protein through genuinely different biochemical pathways—proteolytic cleavage and disulfide bond disruption, respectively. The BromAc combination has been validated against live Omicron virus in human clinical samples. Both compounds have decades of safety data. The missing piece remains the same as with nattokinase: no published RCT has directly measured clinical outcomes of oral bromelain or NAC for spike protein clearance in long COVID patients.

This article is for informational purposes only and does not constitute medical advice.

References

1. Sagar S, et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clin Transl Med. 2021;11(2):e281.
2. Matos AD, et al. Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron. Sci Rep. 2025;15:11493.
3. Pastore A, et al. Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl cysteine. J Biomol Struct Dyn. 2024;42(10):5042–5052.
4. Moolla S, et al. Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption. PNAS. 2022;119(6):e2120419119.
5. Akhter J, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021;13(3):425.
6. Shenoy V, et al. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. Cureus. 2023;15(11):e49204.

Related Reading:

• Nattokinase and Spike Protein: What the Science Says
• The Complete Spike Protein Detox Protocol: Evidence Review
• How to Choose Quality Nattokinase: Testing Guide